Europe's health security apparatus rarely gets a single meeting point where regulators, biotech founders and public health officials sit at the same table. HERA Industry Days 2026 is designed to be that point. Organised by the European Commission's Health Emergency Preparedness and Response Authority, the event has become the agency's central annual gathering for stakeholders working on medical countermeasures and crisis-response capacity.
Why a Dedicated Forum Matters
Health emergencies rarely respect institutional boundaries. A shortage of antivirals, a gap in vaccine manufacturing capacity, or a slow procurement process can turn a contained outbreak into a continental problem. HERA was established precisely to address these structural weaknesses, acting as the EU's coordinating body for anticipating threats and securing access to vaccines, therapeutics, diagnostics and other countermeasures before a crisis peaks rather than after. Industry Days functions as the practical, face-to-face extension of that mandate - a setting where policy intentions meet the operational realities of companies that actually manufacture and distribute these products.
Who Shows Up and Why
The event draws a deliberately broad mix of participants, reflecting how fragmented health preparedness work tends to be across sectors:
- Established pharmaceutical and medtech companies with manufacturing and distribution capacity
- Start-ups and research teams developing diagnostics, therapeutics or novel production methods
- EU institutions and national public authorities responsible for procurement and regulatory oversight
- Investors and funding bodies assessing where public money and private capital can combine effectively
This composition matters because health security is not purely a scientific challenge. It is equally a question of financing, regulatory alignment and supply-chain resilience. A start-up with a promising diagnostic tool is of limited use to the public if it cannot scale production or navigate procurement rules fast enough during an emergency.
Funding, Procurement and the Public-Private Balance
Discussions at this type of event typically centre on how public funding instruments can de-risk early-stage innovation without distorting competitive markets. Public authorities need guaranteed access to countermeasures during emergencies; companies need predictable demand signals to justify investment in manufacturing capacity that may sit idle in ordinary times. That tension - between commercial viability and public-interest stockpiling - sits at the heart of most EU health-preparedness policy debates, and it shapes how contracts, joint procurement schemes and advance purchase agreements are structured.
Networking as Infrastructure
Beyond formal panels, the networking component serves a concrete function. Biotech and medtech ventures often struggle less with scientific development than with finding the right regulatory contacts or co-investors at the right moment. Bringing these groups into the same physical space, even briefly, can shorten the distance between a promising prototype and a deployable product - a gap that, in the context of health emergencies, carries direct consequences for public safety and response speed.